Compound News and Research

RSS

Cornerstone Pharmaceuticals closes $6.17M Series B-4 private equity financing

Cornerstone Pharmaceuticals Inc., a privately held, clinical stage oncology-focused pharmaceutical company, has announced the closing of its Series B-4 private equity financing of $6,175,000. The Company plans to use the proceeds for its on-going phase I/II clinical trials of its lead cancer drug--CPI-613, research and development, and general corporate purposes.

27 Jan 2010

caprotec bioanalytics launches three new caproKits based on its CCMS technology

caprotec bioanalytics announced today the commercial launch of three new caproKits(TM), enabling the discovery, identification and characterization of proteins belonging to the groups of metallo-proteases, histon-deacetylases and GDP/GTP binding proteins.

27 Jan 2010

Halozyme Therapeutics and BioAtla sign research collaboration agreement

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the signing of an exclusive, worldwide, contract research collaboration agreement with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation.

25 Jan 2010

GSK announces new initiatives for addressing healthcare challenges in the world's poorest countries

Andrew Witty, Chief Executive of GlaxoSmithKline, today announced a series of new initiatives targeted at further transforming the company's approach to diseases that disproportionately affect the world's poorest countries. His announcements build on commitments made in 2009 to work in partnership, expand access to medicines and encourage new research into neglected tropical diseases.

22 Jan 2010

ACS Chemical Biology report supports zebrafish for drug development

By combining the tools of medicinal chemistry and zebrafish biology, a team of Vanderbilt investigators has identified compounds that may offer therapeutic leads for bone-related diseases and cancer.

22 Jan 2010

hESC "reporter" line to measure endothelial cell production and activity

New York Stem Cell Foundation (NYSCF)-Druckenmiller Fellow, Daylon James, PhD, of Weill Cornell Medial College, is lead author on a study defining conditions for generating a plentiful supply of endothelial (vessel lining) cells that are suitable for therapeutic use. Dr. James and his colleagues created a human embryonic stem cell (hESC) "reporter" line that can be used to measure endothelial cell production and activity.

22 Jan 2010

NicOx receives EMEA approval for naproxcinod MAA

NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.

22 Jan 2010

Watson Pharmaceuticals provides detailed overview of its global operations at Investor Day meeting in NY

Watson Pharmaceuticals, Inc. today provided a detailed overview of its expanded global operations, enhanced supply chain capabilities and commercial and pipeline developments in its Brand and Generics businesses during an Investor Day meeting held in New York, NY.

22 Jan 2010

Findings may aid in developing therapeutic drugs for stroke and other neurodegenerative diseases

Biomedical scientists from the University of Central Florida and Louisiana State University have identified a way to block a "cell death signal" that they believe triggers brain damage during strokes.

22 Jan 2010

Ipsen and Inspiration Biopharmaceuticals form strategic partnership

Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today announced the formation of a strategic partnership between Ipsen and Inspiration Biopharmaceuticals ("Inspiration") to create a world leading hemophilia franchise, an important milestone for the Celtic Pharma portfolio.

21 Jan 2010

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

In a significant step toward restoring healthy blood circulation to treat a variety of diseases, a team of scientists at Weill Cornell Medical College has developed a new technique and described a novel mechanism for turning human embryonic and pluripotent stem cells into plentiful, functional endothelial cells, which are critical to the formation of blood vessels.

21 Jan 2010

Discovery of new class of compounds may help fight hepatitis C

Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus’s propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.

21 Jan 2010

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

4SC AG, a drug discovery and development company, today announced the start of dosing in a First-in-Man Phase I study in healthy volunteers evaluating 4SC-203, a novel multi-target kinase inhibitor, with particular specificity against selected kinases, including FMS-like tyrosine kinase 3 (FLT3), FLT3 mutants and vascular endothelial growth factor receptors (VEGF-R).

21 Jan 2010

Healthcare industry in Asia Pacific to grow up to US$349 billion by 2012

Frost & Sullivan believes that the healthcare industry is undergoing a paradigm shift from "sickness care" to "wellness". Focused on the 5 Ps – Preventive, Pre-emptive, Personalized, Predictive and Personal Responsibility – the healthcare industry in Asia Pacific is expected to grow to US$349 billion by 2012.

21 Jan 2010

GSK to offer scientists access to compounds, lab space to fight malaria

Drugmaker GlaxoSmithKline (GSK)'s Chief Executive Officer Andrew Witty on Tuesday unveiled the company's plans to allow "free access to its library of 13,500 potential malaria treatments and devote the profits from its experimental [RTS,S] vaccine to battling tropical illnesses that beset poor countries," Bloomberg reports (Randall, 1/20).

21 Jan 2010

AMRI’s Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

SAFEBRIDGE® CONSULTANTS, INC., headquartered in Mountain View, California, has announced that AMRI’s high potency research laboratories and GMP-manufacturing facilities in Rensselaer, New York have met the criteria established under the SafeBridge program for “Potent Compound Safety Certification” and have been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients (“APIs”).

20 Jan 2010

HSF1A stimulates more protein chaperones and reduces protein misfolding

Scientists at Duke University Medical Center have found some compounds that improve a cell's ability to properly "fold" proteins and could lead to promising drugs for degenerative nerve diseases, including Huntington's disease, Alzheimer's disease and Parkinson's disease.

20 Jan 2010

European Patent Office grants a patent for Rexahn Pharmaceuticals' RX-3117

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117.

20 Jan 2010

Statins may protect SCD children from pneumococcal infection

New research suggests a family of widely used cholesterol-lowering drugs might help protect individuals from serious illness following bacterial infection, including the pneumococcal infections that pose a deadly threat to those with sickle cell disease.

20 Jan 2010

Rescue, relief efforts continue in Haiti, 200,000 people estimated to have perished in quake

Rescue efforts continue in Haiti after a major earthquake hit the country last week, CNN reports (1/18). While teams still search for survivors under the rubble, the priority is shifting to relief for those who survived the quake, according to Nicholas Reader, spokesperson for the U.N. Offices for the Coordination of Humanitarian Affairs, TIME reports (Newton-Small, 1/18).

20 Jan 2010